Experimental obesity drug targets appetite and metabolism in early trial
NCT ID NCT06313528
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This completed Phase 1 study tested an experimental drug called LY3437943 against a placebo in 85 people with obesity. Participants were under calorie restriction, and researchers measured how the drug affected calorie intake, energy metabolism, and appetite over up to 6 months. The goal is to see if the drug can help with weight control by reducing hunger and boosting energy use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AdventHealth Orlando
Orlando, Florida, 32804, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3437943 (an experimental drug for obesity)
What this could lead to
If successful, this could point toward a new treatment option for obesity that helps control appetite and energy use.
What could go wrong
This is an early Phase 1 study with only 85 participants, so results may not apply broadly. The drug may not show meaningful benefits or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.